Physician profile
Dani Korya
NPI 1235426347
$5,810.64
in general payments reported to CMS, 2019-2025
27 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $579 · 2021: $1,095 · 2022: $2,470 · 2023: $209 · 2024: $117 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hyperfine Operations, INC. | $1,600.00 | 2022 | |
| Emd Serono, INC. | $661.13 | 2019-2020 | |
| Biogen, INC. | $307.45 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $304.62 | 2021-2023 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $299.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $291.78 | 2022 | |
| Pfizer INC. | $258.64 | 2023-2025 | |
| Stryker Corporation | $241.03 | 2021 | |
| Viz.Ai, INC. | $202.25 | 2022 | |
| Sk Life Science, INC. | $188.91 | 2020-2021 | |
| Stability Biologics, LLC | $166.89 | 2022-2023 | |
| Monteris Medical Corporation | $145.89 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $139.16 | 2021 | |
| Supernus Pharmaceuticals, INC. | $135.16 | 2020 | |
| W. L. Gore & Associates, INC. | $128.51 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $127.63 | 2019 | |
| Abbvie INC. | $125.00 | 2021 | |
| Livanova USA, INC. | $121.03 | 2019-2020 | |
| Allergan, INC. | $83.53 | 2020 | |
| Medtronic USA, INC. | $74.44 | 2019 | |
| Eisai INC. | $68.82 | 2024 | |
| Medtronic, INC. | $38.06 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.75 | 2019-2020 | |
| Lilly USA, LLC | $26.66 | 2019 | |
| Acadia Pharmaceuticals INC | $16.23 | 2022 | |
| Bioventus LLC | $15.16 | 2025 | Durolane |
| Amgen INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$225,487.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dani Korya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.